Loading…
Hefei maker of orthokeratology lenses, overnight-wear contact lenses that slow myopia progression, with a growing chain of eye clinics.
Hefei maker of orthokeratology lenses, overnight-wear contact lenses that slow myopia progression, with a growing chain of eye clinics.
Sells orthokeratology lenses, hard contact lenses worn overnight to reshape the cornea and slow myopia in children, through hospitals and optometry clinics, alongside lens-care products. It has also built its own chain of eye hospitals and clinics, so part of income now comes from eye-care services.
Moat: narrow (regulatory licence, distribution). Licensed OK-lens maker with hospital and clinic channels; device approval requirements slow new entrants.
Headquarters: Hefei, China · Employees: 3,752
Size Ovctek China (300595.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.42B, the 1708th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.67 on 6 Nov 2026.
Performance Over six months the shares fell 26.0%, against -1.6% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 0.3% over the last twelve months (peer median +10.4%); the operating margin is 27.6% (peer median 7.0%).
Valuation It trades at 20.8× forward earnings against a peer median of 23.6× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points above its cost of capital (12.8% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.82B | CN¥1.85B | CN¥1.80B | CN¥1.73B | CN¥1.51B |
| Revenue growth | — | +3% | +4% | +14% | — |
| Gross profit | CN¥1.35B | CN¥1.21B | CN¥1.20B | CN¥1.19B | CN¥1.07B |
| EBITDA | n/a | CN¥813M | CN¥835M | CN¥864M | CN¥805M |
| Net income | CN¥440M | CN¥480M | CN¥572M | CN¥667M | CN¥624M |
| Free cash flow | CN¥668M | CN¥707M | CN¥591M | CN¥645M | CN¥566M |
| Capital expenditure | CN¥84.2M | CN¥121M | CN¥207M | CN¥198M | CN¥129M |
| Total debt | CN¥196M | CN¥308M | CN¥367M | CN¥345M | CN¥298M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ovctek China 300595.SZ | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% |
| Eyebright Medical Technology (Beijing) 688050.SS | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% |
| Menicon 7780.T | $854M | +12% | +5% | 9% | 19.3× | n/a |
| Cooper Companies (The) COO | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300595.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.1% | +4.7% | 8th highest of 21 |
| 6-month return | -26.0% | -1.6% | 4th lowest of 21 |
| Distance from 52-week high | -38.6% | -26.4% | 5th lowest of 21 |
| Revenue growth (TTM) | +0.3% | +10.4% | 4th lowest of 20 |
| Operating margin | 27.6% | 7.0% | 5th highest of 20 |
| Forward P/E | 20.8× | 23.6× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 9.9% | 10.8% | 6th least demanding of 13 |
| Growth delivered (Del g) | +16.5% | +21.1% | 5th lowest of 13 |
| Hurdle (Req g minus delivered) | -6.6 pp | -5.2 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | +0.1 pp | +1.4 pp | 9th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |